The USFDA has given the green light to Merck's pembrolizumab and berahyaluronidase alfa-pmph, marketed as Keytruda Qlex, a skin injection version of its blockbuster drug Keytruda. The decision is a significant step towards increasing patient access to cancer care by cutting administrative time and diversifying treatment options. 

Pembrolizumab, sold as Keytruda, is a cornerstone of modern oncology. Until now, it has only been offered by intravenous (IV) infusion, which normally takes 30 minutes in a clinic. With the new permission, the medicine can now be administered as a subcutaneous injection into the thigh or belly in about one to two minutes. 

"This approval is significant for patients and health care providers like me who have been using immunotherapies for years to treat certain cancers," said Dr J. Thaddeus Beck, an oncologist and Medical Director of the Highlands Clinical Trials Office. 

"We now have a new option … that can be administered in one minute every three weeks or two minutes every six weeks," he added.

The approval came from Study 3475A-D77, a Phase 3 trial for patients with metastatic non-small cell lung cancer (NSCLC) who had not received In addition to chemotherapy, patients received either subcutaneous Keytruda QLEX or intravenous pembrolizumab. The study found that blood concentrations of pembrolizumab were comparable between the two groups. 

In terms of results, the subcutaneous and IV versions had almost identical response rates of 45% and 42%, respectively. There were no significant differences seen in progression-free survival (PFS) or overall survival (OS). The safety profile was also similar to that of IV Keytruda, with the most prevalent adverse effects being nausea, exhaustion, and musculoskeletal pain. 

The subcutaneous version of pembrolizumab, like the IV version, is associated with immune-mediated adverse effects that can affect numerous organs and be severe or fatal. These include pneumonia, colitis, and hepatitis. The medicine is also contraindicated in people with hypersensitivity to its components and offers a risk to pregnant women. Early diagnosis and treatment of immune-related problems remain critical. 

Beyond convenience, experts see broader consequences for patient access. Subcutaneous delivery may be especially beneficial for individuals who do not have a port, have poor venous access, or live in areas with inadequate infusion infrastructure. 

Merck's Dr Marjorie Green, senior vice president and head of oncology, global clinical development, stated that their new injectable immunotherapy option, Keytruda QLEX, has similar results to Keytruda and can be administered in just one minute. 

Patient advocates emphasised its significance. "Developments in subcutaneous cancer treatment that shorten administration time may allow for more patients to receive treatment in multiple health care settings," stated Sally Werner, CEO of Cancer Support Community. 

With roughly 20 million new cancer cases diagnosed worldwide each year, technologies that improve therapy delivery are becoming increasingly important. While IV infusion is still common in many areas, the addition of a subcutaneous alternative could alter care models, making life-saving medicines more accessible and less burdensome. 

However, as with all immunotherapies, balancing convenience with safety concerns will continue to be a defining challenge.